Nerve

Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Retrieved on: 
火曜日, 5月 7, 2024
FDA, Amyloid beta, Part, Total, PIPE, CDER, Transferrin receptor, Nerve, BBB, CSF, Biomarker, Gamma, Enzyme replacement therapy, Traffic barrier, Hunting, OTV, PTV, Food, MGH, IDS, Conference, MAPT, ALS, Therapy, Cerebrospinal fluid, SAN, MPS II, Hospital, Safety, AFL, SGSH, UC, Alpha-synuclein, LUMA, SNCA, Clinical trial, Glycogen storage disease, Neurodegenerative disease, MPS, COMPASS, Patient, Alfa, Acquisition, ETV, ATV, Hunter syndrome, Sanofi, Massachusetts General Hospital, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the first quarter ended March 31, 2024, and provided business highlights.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the first quarter ended March 31, 2024, and provided business highlights.
  • There was no collaboration revenue for the quarter ended March 31, 2024, compared to $35.1 million for the quarter ended March 31, 2023.
  • Total research and development expenses were $107.0 million for the quarter ended March 31, 2024, compared to $128.8 million for the quarter ended March 31, 2023.
  • General and administrative expenses were $25.2 million for the quarter ended March 31, 2024, compared to $27.1 million for the quarter ended March 31, 2023.

Muscle Stimulator Market Projected to Reach $925.48 million by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
金曜日, 5月 3, 2024
TENS, Pain, Brain, Lactic acid, Inflammation, Stroke, Mobile device, Investment, EMS, Acceleration, Functional electrical stimulation, Hope, Sport, MENS, Traction, Table, System, Omron, Intelligence, Injury, Nerve, Pain management, BMAC, Optimism, Physical fitness, Electrical muscle stimulation, NMES, Movement, Athlete, Regeneration, Tetraplegia, Quality of life, Growth, Medical device

However, the muscle stimulator market does face hurdles, including stringent regulatory measures and competition from other therapeutic modalities and fitness equipment.

Key Points: 
  • However, the muscle stimulator market does face hurdles, including stringent regulatory measures and competition from other therapeutic modalities and fitness equipment.
  • This market scenario highlights a collective movement toward embracing muscle stimulator technologies for enhanced physical well-being and recovery.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Muscle Stimulator Market.
  • "Dive into the Muscle Stimulator Market Landscape: Explore 194 Pages of Insights, 922 Tables, and 26 Figures"

Muscle Stimulator Market Projected to Reach $925.48 million by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
金曜日, 5月 3, 2024
TENS, Pain, Brain, Lactic acid, Inflammation, Stroke, Mobile device, Investment, EMS, Acceleration, Functional electrical stimulation, Hope, Sport, MENS, Traction, Table, System, Omron, Intelligence, Injury, Nerve, Pain management, BMAC, Optimism, Physical fitness, Electrical muscle stimulation, NMES, Movement, Athlete, Regeneration, Tetraplegia, Quality of life, Growth, Medical device

However, the muscle stimulator market does face hurdles, including stringent regulatory measures and competition from other therapeutic modalities and fitness equipment.

Key Points: 
  • However, the muscle stimulator market does face hurdles, including stringent regulatory measures and competition from other therapeutic modalities and fitness equipment.
  • This market scenario highlights a collective movement toward embracing muscle stimulator technologies for enhanced physical well-being and recovery.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Muscle Stimulator Market.
  • "Dive into the Muscle Stimulator Market Landscape: Explore 194 Pages of Insights, 922 Tables, and 26 Figures"

Small Molecule Shows Early-Stage Promise for Repairing Myelin Sheath Damage

Retrieved on: 
木曜日, 5月 2, 2024
Nerve, Brain, Enzyme, University, Cell nucleus, Mouse, Tissue, H3K9me3, Organoid, Thought, H3K27ac, Doctor of Philosophy, Axon, Research, Remyelination, Disease, OLS, Cholesterol, Movement, Gene expression, Multiple sclerosis, Regeneration, Ageing, H3K27me3, Tetraplegia, Pharmaceutical industry

CINCINNATI, May 2, 2024 /PRNewswire/ -- When treated with a novel protein function inhibitor called ESI1, mice that mimic the symptoms of multiple sclerosis (MS) and lab-prepared human brain cells both demonstrated the ability to regenerate vital myelin coatings that protect healthy axon function.

Key Points: 
  • When the protective myelin gets damaged, be it by disease or the wear and tear of age, nerve signaling gets disrupted.
  • Pinning down the genetic changes and signals involved in the repair silencing process and finding a small molecule compound that can reverse the silencing was a complex undertaking.
  • In both aging mice and mice mimicking MS, the ESI1 treatment prompted myelin sheath production and improved lost neurological function.
  • When the organoids were exposed to ESI1, the treatment extended the myelin sheath of myelinating cells, the study reports.

Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting

Retrieved on: 
水曜日, 4月 17, 2024
Molecule, Neuroimaging, American Academy, Brain, Iron, Oxidative stress, MSA, AFL, Poster, Disease, Vanderbilt University, Substantia nigra, Plasma, ASX, Pathology, Neurofilament, Forecasting, Macaque, Nerve, Multiple system atrophy, Patient, Treatment, Observational study, AAN, CSF, Neuron, Biomarker, Annual general meeting, Vanderbilt University Medical Center, Therapy, Cerebrospinal fluid, Parkinsonism, ATH, Frasier, SAN, Medical imaging

MELBOURNE, Australia and SAN FRANCISCO, April 17, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that three posters were presented at the American Academy of Neurology (AAN) 2024 Annual Meeting taking place April 13-18, 2024, in Denver, Colorado, USA. Featured presentations described the Company’s work in Parkinson’s disease and Multiple System Atrophy (MSA), including initial biomarker data and baseline characteristics from the ATH434-201 Phase 2 clinical trial.

Key Points: 
  • Featured presentations described the Company’s work in Parkinson’s disease and Multiple System Atrophy (MSA), including initial biomarker data and baseline characteristics from the ATH434-201 Phase 2 clinical trial.
  • At AAN we reported the baseline characteristics from our ATH434-201 Phase 2 trial including fluid biomarkers and neuroimaging data.
  • The data showed increased iron in areas of pathology and elevated plasma Neurofilament Light Chain (NfL) levels at baseline that correlated significantly with disease severity.
  • Plasma NfL significantly increased over 12 months, and both plasma and CSF NfL were associated with disease progression in MSA.

U.S. Department of Health and Human Services Awards Kaléo with Contract to Develop Next Generation Organophosphate Nerve Agent Poisoning Countermeasure

Retrieved on: 
水曜日, 4月 17, 2024
FDA, Administration, ASPR, HHS, The Reconstruction (1970 film), Food, Nerve, ROCS, Development, Naloxone, Government, Food and Drug Administration

The full development contract with options totals $27.7 million.

Key Points: 
  • The full development contract with options totals $27.7 million.
  • Kaléo is a market leader in emergency use auto-injectors with more than 12 million devices manufactured to meet the FDA’s standard of 99.999% device reliability.
  • “The development of a novel, next generation pralidoxime chloride auto-injector is an exciting opportunity,” said Mark A. Herzog, Kaléo’s vice president of global corporate affairs, defense and homeland security.
  • The 2-PAM auto-injector is the third U.S. government medical countermeasure contract awarded to Kaléo in the last five years.

Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024

Retrieved on: 
火曜日, 4月 16, 2024
Axogen, Internet, Webcast, Nerve

ALACHUA, Fla. and TAMPA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2024 financial results on Thursday, May 2, 2024, before the market opens.

Key Points: 
  • ALACHUA, Fla. and TAMPA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2024 financial results on Thursday, May 2, 2024, before the market opens.
  • Axogen management will host an investment-community conference call and webcast at 8 a.m.
  • Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or using the direct dial-in number at (201) 689-8795.
  • Those interested in listening to the conference call live via the Internet may do so by visiting the Investors page of the Company's website at www.axogeninc.com and clicking on the webcast link.

Raydiant Oximetry Secures FDA Approval for Lumerah Investigational Device Exemption (IDE) Study

Retrieved on: 
水曜日, 4月 10, 2024
FDA, Nerve, Bangladesh Technical Education Board, Investment, Eastern Virginia Medical School, EFS, Pregnancy, NIH, DSM-IV codes, IDE, American Journal, NICHD, Trial of the century, Infant, Dean (education), Female, Obstetrics, Gynaecology, EVMS, CTG, Fetal distress, Pulse oximetry, Mother, Organization, SAN, Woman

“Each year 36,000 babies in the United States suffer neurological damage, which could be prevented through better monitoring tools, such as Lumerah,” says Raydiant Oximetry founder and CEO, Dr. Neil P. Ray.

Key Points: 
  • “Each year 36,000 babies in the United States suffer neurological damage, which could be prevented through better monitoring tools, such as Lumerah,” says Raydiant Oximetry founder and CEO, Dr. Neil P. Ray.
  • Lumerah has received FDA Breakthrough Device Designation for expedited market approval.
  • Completion of the EFS study will pave the path towards FDA IDE approval for a subsequent pivotal study.
  • Raydiant Oximetry is supported by leading organizations that include the March of Dimes and the National Institutes of Health (NIH).

Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw

Retrieved on: 
月曜日, 4月 15, 2024
Neurodegenerative disease, Nerve, Hospital, Blood, AFL, Brain, LH, Glioblastoma, GFAP, TBI, Alzheimer's disease, Disease, Injury, Astrocyte, Physician, Multiple sclerosis, Health, Traumatic brain injury, Biomarker, Glial fibrillary acidic protein, Medical imaging

BURLINGTON, N.C., April 15, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the availability of the nation's first test for glial fibrillary acidic protein (GFAP), a critical blood-based biomarker for the early detection of neurodegenerative diseases and neurological injuries.

Key Points: 
  • The new GFAP test – a first-of-its-kind test to be offered commercially nationwide – offers physicians a more efficient pathway to assess the presence and progression of neurodegenerative diseases such as Alzheimer's disease, multiple sclerosis, glioblastoma and injuries like traumatic brain injury (TBI).
  • The biomarker test also expands on Labcorp's comprehensive neurology portfolio, which includes biomarker tests for neurofilament light chain (NfL), pTau181, pTau217 and beta amyloid 42/40.
  • "The introduction of the GFAP biomarker test marks a significant milestone for Labcorp, extending our leadership in the rapidly accelerating field of blood-based biomarkers for neurodegenerative diseases," said Dr. Brian Caveney, Labcorp's chief medical and scientific officer.
  • In the context of neurodegenerative disease or injury, astrocytes release GFAP into the blood, allowing brain injury and disease to be assessed through a simple blood draw.

VSEAT's noseless bike seat to appear on ABC's Shark Tank on April 12

Retrieved on: 
月曜日, 4月 8, 2024
Erectile dysfunction, Nerve, Perineum, Health, DEL, ABC, Groin, Interview, Pressure, SAP, Hulu, Tune, Shark Tank, Television

MARINA DEL REY, Calif., April 8, 2024 /PRNewswire/ -- VSEAT®, creators of the revolutionary noseless and bumpless bicycle seat, is proud to announce its upcoming appearance on ABC's Shark Tank. Watch founders Ani Armstrong and Bryan Visintin present their innovative design to the Sharks on Friday, April 12 at 8 PM ET on ABC and stream on Hulu the following day.

Key Points: 
  • MARINA DEL REY, Calif., April 8, 2024 /PRNewswire/ -- VSEAT® , creators of the revolutionary noseless and bumpless bicycle seat, is proud to announce its upcoming appearance on ABC's Shark Tank.
  • That is until Ani cited persistent pain from her bike seat.
  • Tune in to ABC on Friday, April 12 at 8 PM ET/PT to watch the VSEAT® on Shark Tank.
  • For more information or to arrange an interview with the founders, please email Andrew Luftglass at [email protected] .